BIMI International Medical Inc. (BIMI)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -15.33 Million USD | -53.28% |
| 2021 | -31.97 Million USD | -118.31% |
| 2020 | -3.21 Million USD | -87.83% |
| 2019 | -1.71 Million USD | 87.13% |
| 2018 | -15.54 Million USD | -5493.25% |
| 2017 | -277.91 Thousand USD | 40.62% |
| 2016 | -481.86 Thousand USD | -172.58% |
| 2015 | 633.04 Thousand USD | 21.3% |
| 2014 | 468.46 Thousand USD | -57.61% |
| 2013 | 1.29 Million USD | -13.0% |
| 2012 | 1.44 Million USD | -56.48% |
| 2011 | 3.31 Million USD | -44.78% |
| 2010 | 5.99 Million USD | 1.09% |
| 2009 | 5.94 Million USD | 63.21% |
| 2008 | 3.63 Million USD | 57.14% |
| 2007 | 2.32 Million USD | 72.37% |
| 2006 | 1.35 Million USD | 484.73% |
| 2005 | -348.86 Thousand USD | -11.29% |
| 2004 | -313.46 Thousand USD | -8.87% |
| 2003 | -287.91 Thousand USD | 11.94% |
| 2002 | -326.97 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -773.66 Thousand USD | 68.83% |
| 2023 Q2 | 1.34 Million USD | 274.36% |
| 2023 Q3 | -3.2 Million USD | -337.51% |
| 2022 Q4 | -2.48 Million USD | 30.71% |
| 2022 FY | - USD | -53.28% |
| 2022 Q3 | -3.58 Million USD | 32.1% |
| 2022 Q1 | -2.51 Million USD | 91.46% |
| 2022 Q2 | -5.27 Million USD | -109.54% |
| 2021 Q2 | -85.75 Thousand USD | 97.31% |
| 2021 Q1 | -3.19 Million USD | 32.57% |
| 2021 FY | - USD | -118.31% |
| 2021 Q3 | -1.55 Million USD | -1718.25% |
| 2021 Q4 | -29.47 Million USD | -1790.0% |
| 2020 Q1 | -1.54 Million USD | -104.12% |
| 2020 Q3 | -1.12 Million USD | -121.88% |
| 2020 Q4 | -4.73 Million USD | -318.99% |
| 2020 FY | - USD | -87.83% |
| 2020 Q2 | 5.16 Million USD | 434.65% |
| 2019 Q1 | -171.6 Thousand USD | 98.78% |
| 2019 FY | - USD | 87.13% |
| 2019 Q4 | -755.86 Thousand USD | -390.04% |
| 2019 Q3 | -154.24 Thousand USD | 66.78% |
| 2019 Q2 | -464.36 Thousand USD | -170.6% |
| 2018 FY | - USD | -5493.25% |
| 2018 Q1 | -167.31 Thousand USD | -240.16% |
| 2018 Q2 | -1.29 Million USD | -674.51% |
| 2018 Q3 | -22.61 Thousand USD | 98.25% |
| 2018 Q4 | -14.05 Million USD | -62070.56% |
| 2017 FY | - USD | 40.62% |
| 2017 Q2 | 40.81 Thousand USD | 129.04% |
| 2017 Q1 | -140.52 Thousand USD | -24.43% |
| 2017 Q3 | -129.01 Thousand USD | -416.13% |
| 2017 Q4 | -49.18 Thousand USD | 61.88% |
| 2016 Q2 | -47.44 Thousand USD | 68.43% |
| 2016 FY | - USD | -172.58% |
| 2016 Q1 | -150.26 Thousand USD | 60.01% |
| 2016 Q4 | -112.93 Thousand USD | 28.22% |
| 2016 Q3 | -157.33 Thousand USD | -231.64% |
| 2015 Q1 | 248.51 Thousand USD | 179.54% |
| 2015 Q3 | 426.22 Thousand USD | 23.23% |
| 2015 FY | - USD | 21.3% |
| 2015 Q4 | -375.78 Thousand USD | -188.17% |
| 2015 Q2 | 345.86 Thousand USD | 39.17% |
| 2014 Q1 | 204.95 Thousand USD | 127.04% |
| 2014 FY | - USD | -57.61% |
| 2014 Q2 | -52.14 Thousand USD | -125.44% |
| 2014 Q4 | -312.44 Thousand USD | -145.2% |
| 2014 Q3 | 691.25 Thousand USD | 1425.66% |
| 2013 Q2 | 387.78 Thousand USD | 28.47% |
| 2013 Q3 | 474.05 Thousand USD | 22.25% |
| 2013 Q4 | 90.27 Thousand USD | -80.96% |
| 2013 Q1 | 301.84 Thousand USD | -18.75% |
| 2013 FY | - USD | -13.0% |
| 2012 Q3 | 306.9 Thousand USD | -31.53% |
| 2012 FY | - USD | -56.48% |
| 2012 Q4 | 371.51 Thousand USD | 21.05% |
| 2012 Q1 | 314.76 Thousand USD | -79.64% |
| 2012 Q2 | 448.2 Thousand USD | 42.39% |
| 2011 Q3 | 324.51 Thousand USD | -60.67% |
| 2011 Q1 | 616.63 Thousand USD | -33.66% |
| 2011 FY | - USD | -44.78% |
| 2011 Q4 | 1.54 Million USD | 376.32% |
| 2011 Q2 | 825.19 Thousand USD | 33.82% |
| 2010 FY | - USD | 1.09% |
| 2010 Q1 | 579.88 Thousand USD | -67.97% |
| 2010 Q2 | 1.88 Million USD | 224.66% |
| 2010 Q3 | 2.6 Million USD | 38.43% |
| 2010 Q4 | 929.49 Thousand USD | -64.34% |
| 2009 Q1 | 549.71 Thousand USD | -25.53% |
| 2009 Q2 | 997.01 Thousand USD | 81.37% |
| 2009 Q3 | 2.57 Million USD | 158.39% |
| 2009 Q4 | 1.81 Million USD | -29.72% |
| 2009 FY | - USD | 63.21% |
| 2008 Q1 | 654.68 Thousand USD | -19.24% |
| 2008 Q4 | 738.2 Thousand USD | -34.35% |
| 2008 Q3 | 1.12 Million USD | 0.72% |
| 2008 Q2 | 1.11 Million USD | 70.53% |
| 2008 FY | - USD | 57.14% |
| 2007 Q4 | 810.66 Thousand USD | 23.56% |
| 2007 Q2 | 884.2 Thousand USD | 2465.32% |
| 2007 Q1 | -37.38 Thousand USD | -102.3% |
| 2007 FY | - USD | 72.37% |
| 2007 Q3 | 656.06 Thousand USD | -25.8% |
| 2006 Q2 | -72.24 Thousand USD | 15.94% |
| 2006 Q3 | -302.56 Thousand USD | -318.79% |
| 2006 Q4 | 1.62 Million USD | 636.52% |
| 2006 FY | - USD | 484.73% |
| 2006 Q1 | -85.94 Thousand USD | -340.32% |
| 2005 Q4 | -19.51 Thousand USD | 85.79% |
| 2005 FY | - USD | -11.29% |
| 2005 Q3 | -137.31 Thousand USD | -61.13% |
| 2005 Q1 | -82.8 Thousand USD | 5.13% |
| 2005 Q2 | -85.22 Thousand USD | -2.92% |
| 2004 Q3 | -93.4 Thousand USD | -17.68% |
| 2004 Q1 | -53.4 Thousand USD | 38.51% |
| 2004 Q2 | -79.37 Thousand USD | -48.63% |
| 2004 FY | - USD | -8.87% |
| 2004 Q4 | -87.28 Thousand USD | 6.56% |
| 2003 FY | - USD | 11.94% |
| 2003 Q4 | -86.85 Thousand USD | -77.75% |
| 2003 Q3 | -48.86 Thousand USD | 51.56% |
| 2003 Q1 | -51.32 Thousand USD | 45.2% |
| 2003 Q2 | -100.87 Thousand USD | -96.54% |
| 2002 Q2 | -77.91 Thousand USD | 23.55% |
| 2002 FY | - USD | 0.0% |
| 2002 Q3 | -53.47 Thousand USD | 31.38% |
| 2002 Q1 | -101.91 Thousand USD | 0.0% |
| 2002 Q4 | -93.66 Thousand USD | -75.17% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 30.702% |
| China Jo-Jo Drugstores, Inc. | 1.22 Million USD | 1350.236% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 9.72 Million USD | 257.754% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 9.72 Million USD | 257.754% |
| Leafly Holdings, Inc. | -5.73 Million USD | -167.5% |
| Leafly Holdings, Inc. | -5.73 Million USD | -167.5% |
| LifeMD, Inc. | -8.21 Million USD | -86.73% |
| LifeMD, Inc. | -8.21 Million USD | -86.73% |
| TRxADE HEALTH, Inc. | -13.72 Million USD | -11.792% |
| PetMed Express, Inc. | -394 Thousand USD | -3793.009% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.864% |